Histogen (FRA:CPH) Other Gross PPE : €0.00 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Histogen Other Gross PPE?

Histogen's Other Gross PPE for the quarter that ended in Sep. 2023 was €0.00 Mil.

Histogen's quarterly Other Gross PPE declined from Mar. 2023 (€5.15 Mil) to Jun. 2023 (€5.01 Mil) and declined from Jun. 2023 (€5.01 Mil) to Sep. 2023 (€0.00 Mil).

Histogen's annual Other Gross PPE declined from Dec. 2020 (€5.34 Mil) to Dec. 2021 (€4.76 Mil) but then increased from Dec. 2021 (€4.76 Mil) to Dec. 2022 (€5.28 Mil).

Histogen Other Gross PPE Historical Data

The historical data trend for Histogen's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Other Gross PPE Chart

Histogen Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Other Gross PPE

1.95

5.34

4.76

5.28

Histogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Other Gross PPE	Get a 7-Day Free Trial													5.73	5.28	5.15	5.01	-

Histogen Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Histogen (FRA:CPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (FRA:CPH) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

HSTO:USA

Address

10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.histogen.com

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Histogen (FRA:CPH) Headlines

No Headlines